Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.

Adam B Weiner | Thiago Vidotto | Yang Liu | Adrianna A Mendes | Daniela C Salles | Farzana A Faisal | Sanjana Murali | Matthew McFarlane | Eddie L Imada | Xin Zhao | Ziwen Li | Elai Davicioni | Luigi Marchionni | Arul M Chinnaiyan | Stephen J Freedland | Daniel E Spratt | Jennifer D Wu | Tamara L Lotan | Edward M Schaeffer
Nature communications | 2021

Black men die more often of prostate cancer yet, interestingly, may derive greater survival benefits from immune-based treatment with sipuleucel-T. Since no signatures of immune-responsiveness exist for prostate cancer, we explored race-based immune-profiles to identify vulnerabilities. Here we show in multiple independent cohorts comprised of over 1,300 patient samples annotated with either self-identified race or genetic ancestry, prostate tumors from Black men or men of African ancestry have increases in plasma cell infiltrate and augmented markers of NK cell activity and IgG expression. These findings are associated with improved recurrence-free survival following surgery and nominate plasma cells as drivers of prostate cancer immune-responsiveness.

Pubmed ID: 33568675

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA212409
  • Agency: NCI NIH HHS, United States
    Id: T32 CA193145
  • Agency: NCI NIH HHS, United States
    Id: U01 CA196390

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions

The Cancer Immunome Database (tool)

RRID:SCR_014508

A database which provides results of comprehensive immunogenomic analyses of next generation sequencing data for 19 solid cancers from The Cancer Genome Atlas and other datasources. The database can be queried for the gene expression of specific immune-related gene sets, cellular composition of immune infiltrates (characterized using gene set enrichment analyses and deconvolution), neoantigens and cancer-germline antigens, HLA types, and tumor heterogeneity (estimated from cancer cell fractions). It also provides survival analyses for different types immunological parameters.

View all literature mentions

QuPath (tool)

RRID:SCR_018257

Open Source software package for digital pathology image analysis. Used for whole slide image analysis and digital pathology. Provides researchers with batch processing and scripting functionality, and extensible platform with which to develop and share new algorithms to analyze complex tissue images.

View all literature mentions